Abstract
Cervical cancer is an extremely prevalent disease worldwide. The purpose of this study was to illustrate the relationship between methylenetetrahydrofolate reductase (MTHFR) polymorphisms or methionine synthase reductase (MTRR) polymorphisms and cervical cancer. There were 372 women who performed genetic and folic acid assessments. For the MTHFR C677T, there was no significant difference in the distribution of C allele and T allele in the three groups. However, the mutant C allele of MTHFR A1298C was significantly higher in the cancer group than in the normal group. Similarly, the mutant G allele of MTRR A66G was also higher than the normal group. The serum folic acid levels were gradually decreased with the development of cervical lesions. Serum folate levels in 4–9 ng/ml and ≤4 ng/ml were both significantly associated with cervical cancer risk. However, the MTHFR C677T polymorphism was not associated with the risk of cervical cancer or CIN. In contrast, the MTHFR A1298C polymorphism could increase the risk of both cervical cancer and CIN. In addition, the MTRR A66G polymorphism was only associated with the risk of cervical cancer but not CIN.
Highlights
Cervical cancer is an extremely prevalent disease worldwide, representing 13% of female cancers
Among the 372 participants in this study, 116 patients with cervical intraepithelial neoplasia (CIN) and 146 cervical cancer patients were compared with the 110 normal women, respectively
Methylenetetrahydrofolate reductase (MTHFR) gene defects would lead to a number of basic biochemical processes of the body disorders, including cell cycle regulation, DNA replication, DNA methylation modification, which may lead to neural tube defects, cancer, cardiovascular and cerebrovascular diseases[13]
Summary
Cervical cancer is an extremely prevalent disease worldwide, representing 13% of female cancers. The incidence of cervical cancer is second among the cancers affecting women[1]. Folate acid deficiency may increase the risk of cancer, such as prostate cancers, colorectal cancer, ovarian cancer, lung cancer, pancreas cancer, cervical cancer and breast cancer[6,7]. Methylenetetrahydrofolate reductase (MTHFR), encoded by the MTHFR gene, is the rate-limiting enzyme in the metabolism of folic acid. The SNPs of MTRR gene: A66G (rs1801394) can decrease MTRR affinity to methionine synthase (MTR)[9]. We performed a large cohort study to evaluate the efficacy of folic acid supplementation and polymorphism MTHFR on developing cervical cancer in China. We anticipate that this report could provide epidemiological evidence and guiding significance of cervical cancer for folate acid supplementation
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
